ABOUT QPS LLC

QPS is an award winning global CRO providing discovery, preclinical and clinical drug development services since 1995. Our mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services in Toxicology, DMPK, Neuropharmacology, Preclinical and Clinical Drug Development.  

At QPS we believe in developing close and long lasting relationships with our clients on the basis of trust and mutual respect. This mutual trust, combined with the nimble approach we offer as a specialty CRO, helps improve the quality of your outsourced clinical work and reduces the degree of required oversight.

Neuropharmacology: QPS offers you the most predictive disease models, as well as unparalleled experience with validated transgenic and non-transgenic in vitro and in vivo models covering the majority of pharmacological targets for Alzheimer’s, Parkinson’s, Huntington’s and other neurodegenerative diseases.

Toxicology: Over the past two decades, QPS has performed thousands of GLP studies for local and international pharmaceutical and biotechnology companies, covering many different disease therapies. This vast experience attests to our ability to effectively deliver high quality toxicology data solutions at our preclinical site in Asia.

DMPK: With immediate access to a team of senior scientists with decades of pharmaceutical and biotech experience, QPS guides you through the appropriate ADME studies across a broad range of compound structures and therapeutic targets.

Bioanalysis: QPS is built on one of the world’s largest capacities in bioanalysis for small molecules and biologics, with state of the art facilities in the U.S., Europe and Asia. Find out how a strategic outsourcing alliance with QPS can provide you with world class operational and service excellence.

Translational Medicine: QPS offers specialized biomarker assay capabilities that enable you to follow targeted therapies and personalized medicines.

Clinical Development: We offer industry-leading early and late phase capabilities, featuring more than 500 phase I beds across the U.S., Europe and Asia. For more than 20 years, QPS’ clinical research sites have collectively completed thousands of clinical trials involving tens of thousands of healthy volunteers and patients. We have studied every conceivable kind of molecular entity, large or small, either as part of a complex, First-in-Man, POC program, or a larger global Phase II-IV study.

VIDEOS

A clinical trial volunteer gives insight on participating in a trial at the QPS Netherlands Clinical from standard procedures when visiting the clinic to financial compensation.

Learn about our Alzheimer's Disease clinical trial process through the eyes of a volunteer at our QPS facility in the Netherlands.

Take a look at our Alzheimer's Disease clinical trial process through the eyes of a doctor at our QPS facility in the Netherlands.

WEBINARS

Join Mariska Beukers of QPS as she discusses the restart of clinical trials in the Netherlands and shares the QPS plan to run efficient and safe trials in this new COVID-19 environment.

Join Mariska Beukers as she thoroughly discusses the clinical study subject flow during COVID-19. These slides follow their strategy as they entered a stay-at-home order, received the restart of clinical trails and developed a plan to open sites for clinical conduct.

This webinar discusses the impact of clinical decisions on revenue in reference based pricing countries.

In this webinar, we provide a comprehensive overview and practical guide to get the most out of your hAME study, covering the many nuanced steps and considerations.

Brendon Bourg and Robin Lee of QPS Missouri walk you through the restart of clinical trials during COVID-19. They provide an overview how the company handled site closures, devised plans to complete ongoing studies safely, identified risks and their thoughts on the future of clinical trials.

CONTACT INFORMATION

QPS LLC

3 Innovation Way, Delaware Technology Park, Suite 240

Newark, DE 19711

UNITED STATES

Phone: 512-350-2827

Contact: Lily Rosa

FEATURED ARTICLES

WHITE PAPERS

  • Biotech and pharmaceutical companies know that the stakes are high when picking a CRO partner. Biotech and pharmaceutical companies that want to feel confident in their CRO choice can do the following as they evaluate candidates:

  • As the number of pediatric trials being conducted increases, there are several challenges confronting parents, guardians, patients and pharmaceutical companies. One of the biggest of these issues is that it is difficult to enroll participants in pediatric trials. However, these five strategies can help make it easier to enroll trial participants and complete successful trials.

  • Just four years ago, the first CGT treatment was approved by the FDA. Today, nine therapies are approved, and, according to PhRMA, the number of treatments in clinical trials increased by 25% over the past year, going from 289 to 362. Even more treatments are in preclinical stages and are expected to enter the clinical trials pipeline. Given this, many biopharmaceutical companies are looking for CRO partners with significant experience conducting CGT-focused clinical studies. Here are five criteria to consider when evaluating organizations.

CASE STUDIES

  • A biotech Sponsor approached QPS to conduct a challenging Phase I study, involving a bolus injection of a rapid onset sedative/anesthetic in healthy volunteers. This case study outlines the challenges faced and the solutions put in place to deliver the study successfully.

  • A biotech client approached QPS to conduct a challenging study that required fast recruitment of a large group of study subjects, split into multiple cohorts, all of whom had very low testosterone. This case study outlines the challenges
    faced and the solutions put in place to deliver the study successfully.

  • A large pharma Sponsor approached QPS to complete recruitment and enrollment of a very small and challenging trial evaluating hepatic function. This case study outlines the challenges faced and the solutions put in place to deliver the study successfully.

  • A Biotech company approached QPS to conduct a trial with healthy volunteers, where those volunteers were required to have a specific level of IgG and needed to remain in the study for a period of 1 year. This case study outlines the challenges faced and the solutions put in place to deliver the study successfully.

  • A large pharma Sponsor approached QPS to jump into a trial early and complete initial phases of recruitment and enrollment into a large, multi-cohort clinical trial. This case study outlines the challenges faced and the solutions put in place to deliver the study successfully.

  • A pharmaceutical client needed to to conduct a challenging Non-Interventional Study (NIS), across 7 countries in Europe. This case study outlines how we successfully provided the Sponsor with a “one shop” solution for this NIS covering 7 European countries with diverging requirements.

  • A biotech client needed to conduct a challenging Phase III study, requiring fast recruitment from multiples sites across Europe. This case study outlines how we achieved the Pan-European recruitment target on time to deliver the study successfully.

  • A biotech sponsor needed to conduct a challenging Phase I SAD/MAD study, involving multiple IV doses over multiple days in healthy volunteers. Read how our team not only delivered a complex study during a difficult recruitment time and meeting all study criteria but also gained a repeat customer.